Antiviral drugs market

Antiviral Drugs Market, by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others), by Type (Branded and Generics), by Application (HIV, Hepatitis, Herpes, Influenza, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Request Free Sample

Feb 2022
CMI4912
189 Pages
Excel & Pdf
Medical Devices

Summary

Antiviral drugs are used for the treatment of viral infections, such as human immunodeficiency virus (HIV), hepatitis, and influenza. Broad-spectrum antiviral drugs can be used to treat a range of viruses.

The increasing approval of drug for the treatment of viral infection is expected to drive the market growth over the forecast period. For instance, in March 2019, GlaxoSmithKline Plc (pharmaceutical company) announced that Viread (tenofovir disoproxil fumarate), an oral antiviral drug for chronic hepatitis B treatment, received approval from the National Medical Products Administration for its updated safety statistics on chronic hepatitis B treatment in pregnant patients.

Moreover, ongoing research and development activities and private investments in the healthcare sector for the introduction of new and effective drugs is expected to positively impact revenue growth of the antiviral drugs market over the forecast period.

The global antiviral drugs market is estimated to be valued at US$ 56,480.7 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).

Figure 1. Global Antiviral Drugs Market Share (%) in Terms of Value, By Region, 2021

Increasing government initiatives for viral infection is expected to drive the market growth over the forecast period.

For instance, in 2017, the U.S. Department of Health And Human Service started the National Viral Hepatitis Action Plan 2017-2020 (Action Plan) to fight against viral hepatitis in the U.S. The plan outlines strategies to achieve three major goals between 2017 and 2020, such as preventing new viral hepatitis infections, reducing deaths, and improving the health of people with viral hepatitis.

Antiviral Drugs Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 56,480.7 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	4.2%	2028 Value Projection:	US$ 75,558.0 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others By Type: Branded, Generics By Application: HIV, Hepatitis, Herpes, Influenza, Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	GlaxoSmithKline plc, AbbVie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Cipla Inc., Aurobindo Pharma, and Gilead Sciences
Growth Drivers:	Increasing prevalence of viral infection Increasing government initiatives for viral infection Rising approval of antiviral drugs
Restraints & Challenges:	High cost of drugs for the treatment of viral infection such as hepatitis

Figure 2. Global Antiviral Drugs Market Share (%), by Application, 2021

The rising government investments in key companies to promote research and development for treatment of viral infection is expected to offer a lucrative opportunity for the market players to develop novel therapeutics for the treatment of viral infection.

For instance, in July 2020, Novavax (biotechnology company) and Regeneron Pharmaceuticals, a biotechnology company, received US$ 2 billion funding from the U.S. federal government to manufacture drugs and vaccines against COVID-19.

Global Antiviral Drugs Market– Impact of Coronavirus (COVID-19) Pandemic- Government Measures to Combat COVID-19

Governments are taking various initiatives to combat COVID-19. For instance, in May 2020, the Centers for Disease Control and Prevention started working with the All-of-Government and All-of-America Approach to increase testing capacity, improve case detection, and contact tracing across all states in the U.S. and to re-open the country.

Moreover, antiviral composites shows activity against COVID-19 virus during the preclinical screening, many pharma company have brought affordable vaccine and drugs for the public emergency pandemic use to give potential immunity to the patients. Governments are giving approval for fast scale-up, which can help them to reopen economics. Till date, there is no potential treatment are available for Covid-19, major companies are trying to use existing drug for novel corona virus.

The use of specific antiviral drug for the treatment of COVID-19 contributes to the growth of antiviral drug market.

Global Antiviral Drugs Market: Restraint

High cost of hepatitis drugs is a major barrier for many patients to receive treatment for this disease. In 2014, the U.S. Food and Drug Administration approved direct-acting antiviral medications for the treatment of hepatitis C disease.

The high cost drugs for hepatitis C –

Harvoni costs US$ 94,500 for a 12-week treatment

Mavyret costs US$ 39,600 for a 12-week treatment

Technivie costs US$ 76,653 for a 12-week treatment

Such high cost treatment is a major restraining factor for antiviral drugs market.

Key Players

Major players operating in the global antiviral drugs market include GlaxoSmithKline plc. AbbVie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Cipla Inc., Aurobindo Pharma, and Gilead Sciences

Table of Content

*Browse 44 market data tables and 39 figures on "Antiviral Drugs Market” - Global forecast to 2028

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global antiviral drugs market during the forecast period (2021-2028)?

The global antiviral drugs market size is estimated to be valued at US$ 56,480.7 million in 2021 and is expected to exhibit a CAGR of 4.2% between 2021 and 2028.

What are the major factors driving the market growth?

Increasing prevalence of viral infection, increasing government initiatives for viral infection, and rising approval of antiviral drugs are expected to drive the market growth over the forecast period.

Which is the leading application segment in the market?

Hepatitis segment is expected to hold the major market share, owing to increasing prevalence of hepatitis disease.

Which region holds the largest market share in the market?

North America holds the largest market share in the market.

What are the key factors hampering growth of the market?

Major factors hampering the growth of the market include high cost of drugs for the treatment of viral infection such as hepatitis.

Which are the major players operating in the market?

Major players operating in the market include GlaxoSmithKline plc., AbbVie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Cipla Inc., Aurobindo Pharma, and Gilead Sciences